Searchable abstracts of presentations at key conferences on calcified tissues

ba0005p410 | Osteoporosis: treatment | ECTS2016

Can bone turnover markers help to define the duration of bisphosphonate drug holidays?

Statham Louise , Aspray Terry , Abdy Sharon

Background: On cessation of bisphosphonate treatment, while bone mineral density decreases slowly, bone resorptive markers such as C-terminal telopeptide (CTX) increase more quickly and may be useful in monitoring ‘offset’ of action. Our aim was to analyse changes in CTX on stopping long-term bisphosphonate treatment to guide clinical decision-making on the duration of treatment cessation (‘drug holidays’).Subjects and methods: A tota...

ba0001pp385 | Osteoporosis: pathophysiology and epidemiology | ECTS2013

Fracture risk assessment in a primary care population: case finding using routine GP data, FRAX® And RAIDR® in the United Kingdom

Aspray Terry , Whalley Erica , Scott Mike , Summers Steve , Turley Steve , Wright Rachel , Maddison Valerie , Abdy Sharon , Kay Lesley

Introduction: Fracture risk assessment using FRAX® estimates 10-year fracture risk (FR10) at major sites (Maj_FR10) and hip (Hip_FR10). In 2012, in Newcastle, UK, a strategy was agreed to share data between General Practice (GP), Clinical Commissioning Groups and local hospitals to identify patients at high FR10.Methods/design: FRAX® and RAID® (a health reporting, analysis and intelligence delive...